阿尔茨海默病诱导的神经元携带PSEN1突变,表现出降低了刺激能力
Simon Maksour1, Rocio K Finol-Urdaneta2, Amy J Hulme2
1School of Chemistry and Molecular Bioscience and Molecular Horizons, University of Wollongong, Wollongong, NSW, Australia.
Frontiers in cellular neuroscience
|October 24, 2024
概括
在早期阿尔茨海默病 (AD) 中,前列林1 (PSEN1) 突变会降低神经元刺激能力. 这项研究揭示了一种离子通道失衡,导致家族性AD (fAD) 中神经元发射受损.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 遗传学 是一个
- 细胞生物学 细胞生物学
背景情况:
- 阿尔茨海默病 (AD) 是一种神经退行性疾病,影响记忆和认知.
- プレセニリン1 (PSEN1) 中的突变是早期家族性AD (fAD) 的主要原因.
- 改变神经元刺激性是阿尔茨海默病的早期指标,但PSEN1突变的联系尚不清楚.
研究的目的:
- 使用诱导的多能干干细胞衍生神经元 (iN) 调查fAD中神经元刺激性的早期变化.
- 检查特定PSEN1突变 (S290C,A246E) 对神经元功能的影响.
- 阐明离子通道改变在PSEN1相关的fAD中的作用.
主要方法:
- 从具有PSEN1突变的fAD患者和CRISPR校正的同位素对照生成了INs.
- 进行了电生理学分析,以评估神经元刺激性.
- 分析了被动膜特性和电压关闭的离子通道电流密度 (Kv和Nav).
主要成果:
- 与对照组相比,PSEN1突变的INs具有较低的整体刺激能力.
- S290C和A246E突变导致了被动膜性质的明显改变.
- 突变的INs显示Kv通道电流密度增加,但与Nav通道电流密度相比较,表明Nav/Kv不平衡.
结论:
- 在fAD中,PSEN1突变会损害神经元刺激能力,可能是通过改变了离子通道功能.
- 观察到的Nav/Kv不平衡导致fAD中神经元发射受损.
- 了解这些早期的细胞变化对于阿尔茨海默病的发病研究至关重要.
相关概念视频
Alzheimer's Disease: Overview
449
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
449
Alzheimer's Disease: Treatment
165
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
165
Neural Regulation
39.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.1K


